- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06804070
The Effects of a Botanical Moisturizer and an Unscented Soap on Eczema and Itch
Clinical and Instrumental Efficacy Evaluation on Eczema of One Cosmetic Product
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gdansk, Poland
- Eurofins Dermscan Poland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Sex: female and male;
- Age : 18 years old and above;
- Phototype: I to IV;
- Type: Caucasian;
- Subjects with active eczema condition the body (showing flakiness, irritation, itch and intense dryness);
- Subjects with a SCORAD of 25 - 50;
- Subjects with dry skin on the study areas;
- Subject barely wearing makeup;
- Subjects must not take antibiotics and / or apply any antifungal treatments (body/scalp) for 1 month before study start and during the entire study duration;
- No change in hygiene, cosmetics, and make-up habits - except for the product(s) under study - during the entire study duration;
- Subjects agreeing not to change lifestyle habits during the study duration.
- Healthy subject;
- Subject having given her free informed, written consent;
- Subject willing to adhere to the protocol and study procedures;
- Subject with Polish citizenship.
Exclusion Criteria:
- For women with childbearing potential: pregnant or nursing woman or woman planning to get pregnant during the study;
- Cutaneous pathology on the study zone (other than eczema);
- Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the study product (the subjects are allowed to use their topical corticosteroids during the study if needed; the information about the treatment and the number of applications must be noted in the daily log);
- Subject having undergone a surgery under general anesthesia within the previous month;
- Excessive exposure to sunlight or UV-rays within the previous month;
- Subject enrolled in another clinical trial during the study period (concerns the studied zones).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Participant
The participant is provided with and instructed to use a botanical moisturizer on the body for the duration of the study.
The participant is also provided with and instructed to use an unscented soap, in replacement of the participant's usual cleansing product for the duration of the study.
|
The intervention includes the use of 2 products:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective and Subjective Scoring of Eczema Severity
Time Frame: 8 weeks
|
Change in eczema severity was assessed using SCORAD (SCOring of Atopic Dermatitis). A. First, the spread of eczema on different body areas is assessed by the investigator and calculated as a percent, where the maximum is 100%. B. Second, the intensity of skin redness, swelling, oozing, scratch marks, skin thickening and dryness is scored by the investigator from 0 to 3, where 0 is none, 1 is mild, 2 is moderate, and 3 is severe. C. Finally, for the subjective score, participants are asked to report the intensity of symptoms (itch and sleeplessness) from 0 to 10, where 0 is no itch or no sleeplessness, and 10 is the worst imaginable itch or insomnia sleeplessness. The total score of the objective SCORAD is obtained with the following formula: SCORAD = A/5 + 7 B/2 + C |
8 weeks
|
|
Localized Eczema Severity
Time Frame: 4 weeks
|
Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI). Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores. |
4 weeks
|
|
Localized Eczema Severity
Time Frame: 8 weeks
|
Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI). Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores. |
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Hydration
Time Frame: 4 weeks
|
Change in skin hydration is assessed with a Corneometer.
|
4 weeks
|
|
Skin Hydration
Time Frame: 8 weeks
|
Change in skin hydration is assessed with a Corneometer.
|
8 weeks
|
|
Transepidermal Water Loss
Time Frame: 4 weeks
|
Change in transepidermal water loss is assessed with a Tewameter TM 300
|
4 weeks
|
|
Transepidermal Water Loss
Time Frame: 8 weeks
|
Change in transepidermal water loss is assessed with a Tewameter TM 300
|
8 weeks
|
|
Desquamation Index
Time Frame: 4 weeks
|
Change in desquamation is assessed with D-Squam®.
|
4 weeks
|
|
Desquamation Index
Time Frame: 8 weeks
|
Change in desquamation is assessed with D-Squam®.
|
8 weeks
|
|
Positive and Negative Affect
Time Frame: 4 weeks
|
Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form). Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely. |
4 weeks
|
|
Positive and Negative Affect
Time Frame: 8 weeks
|
Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form). Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely. |
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- #STUU524AA0147-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis (Eczema)
-
Alphyn BiologicsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Eczema, Atopic | Atopic Dermatitis (AD)Australia
-
Caja Costarricense de Seguro SocialNot yet recruitingAtopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis (AD) | Atopic Dermatitis / Eczema | Atopic Dermatitis, Unspecified | Atopic Dermatitis PatientsCosta Rica
-
En Chu Kong HospitalRecruitingSkin Diseases | Skin Diseases, Genetic | Skin Diseases, Eczematous | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Atopic Dermatitis (AD) | TCMTaiwan
-
Apollo Therapeutics LtdRecruitingDermatitis | Eczema | Dermatitis, Atopic | Atopic Dermatitis | Atopic | Eczema, Atopic | Dermatologic Disease | Eczema Atopic DermatitisUnited States, Spain, Germany, Canada, Bulgaria, Poland, Czechia, Hungary
-
Corvus Pharmaceuticals, Inc.RecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, AtopicUnited States
-
University of California, DavisCompletedAtopic Dermatitis | Hand Eczema | Atopic Eczema | Infantile EczemaUnited States
-
Taipei Medical University Shuang Ho HospitalRecruitingAtopic Dermatitis (Eczema) | Atopic Dermatitis, ProbioticsTaiwan
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
Clinical Trials on Botanical Moisturizer + Unscented Soap
-
Codex Labs CorporationEurofins Dermscan PharmascanCompletedThe Effects of a Botanical Moisturizer, an Oral Supplement, and an Unscented Soap on Eczema and ItchAtopic Dermatitis (Eczema)Poland
-
Codex Labs CorporationEurofins Dermscan PharmascanActive, not recruitingAtopic Dermatitis (Eczema)Poland
-
HALEONCompletedSunscreening AgentsUnited States
-
Integrative Skin Science and ResearchArbonneActive, not recruitingWrinkleUnited States
-
HALEONCompletedSunscreening AgentsUnited States
-
Universitas PadjadjaranCompletedPityriasis VersicolorIndonesia
-
Integrative Skin Science and ResearchArbonneActive, not recruiting
-
GlaxoSmithKlineCompleted
-
Cook County HealthCenters for Disease Control and Prevention; Sage Products, Inc.CompletedPneumonia | Sepsis | Bacteremia | Urinary Tract Infection | Nosocomial Infection | Clostridium InfectionUnited States
-
GlaxoSmithKlineCompletedSunscreening AgentsUnited States